Three approaches to examination give a comprehensive overview
Glaucoma is a progressive optic neuropathy with characteristic damage of the optic nerve head that results in visual field loss. Changes such as loss of retinal ganglion cells, structural and functional alterations of the optic nerve happen in everyone with aging.
However, in patients with glaucoma these changes happen much more quickly and can lead to devastating complications, even to irreversible visual loss if left untreated. That’s why understanding the progression rate of glaucoma is crucial for timely intervention.
We have identified some risk factors for fast progression of the glaucomatous damage which help us recognise patients at higher risk of visual loss. These are the high intraocular pressure, the thin central corneal thickness, the presence of pseudoexfoliation as well as the presence of RNFL hemorrhages.1,2
Moreover, advancing age, African ethnic origin, positive family history, overtreated high blood pressure and diabetes have been associated with glaucoma progression.
Patients with advanced disease or rapid progression require more aggressive treatment strategies and frequent monitoring. (Figure 1)
In order to detect progression of glaucomatous damage, we use clinical, structural and functional examination of the optic nerve.
During clinical examination, the following findings are suggestive of progression:
Color and red-free photography of the optic nerve head can provide a baseline and help track changes over time and is more objective than drawings or notes. That’s why it is always useful to document clinical examination findings using fundus photography. However, we have to consider the fact that the image quality depends on the transparency of the media, the co-operation of the patient and the pigmentation of the fundus and that the interpretation of the findings varies between different examiners.
Structural examination of optic nerve head is performed using spectral domain OCT (SD-OCT).OCT provides objective measurements for the thickness of the nerve fiber layer (RNFL), for optic nerve head parameters (C/D ratio, rim thickness, cup volume) and for the thickness of the ganglion cell layer (GCL).3 Of interest are changes that exceed the scatter of individual measurements and the loss due to physiological ageing. OCT devices4 can provide progression analysis for all these measurements and can give plots that are easy to interpret. Unfortunately, measurements from different SD-OCT devices are not comparable and also no useful information can be provided once a certain threshold value has been reached.
Apart from clinical and structural examination of the optic nerve, visual field testing that measures optic nerve’s function is also crucial in detecting progression. Visual field testing, also known as perimetry, assesses the integrity of a patient’s visual field by measuring their ability to detect stimuli at various locations within their visual field. During testing, patients respond to visual stimuli presented at different intensities and locations, generating a map of their visual field sensitivity. Serial visual field examinations enable clinicians to track changes in visual sensitivity over time, identifying progressive visual field loss indicative of worsening glaucoma.5
Unfortunately, there is no consensus on the best method or threshold and on what amount of change is significant. The variability within a test and over several tests is considerable. Visual field machines have software which provide event-based and trend-based analysis. Event-based analysis can show if there is progression and trend-based analysis can demonstrate how fast the progression is happening (Figure 2). According to the recommendations of the European Glaucoma Society, newly diagnosed glaucoma patients should have three visual field tests per year during the first 2 years after diagnosis to determine rate of progression.
Monitoring the progression rate of glaucoma is integral to preserving visual function and quality of life in affected individuals. Combining structural and functional assessment modalities with trend analysis and patient-specific risk factors enables clinicians to tailor treatment strategies. Regular follow-up and timely intervention are essential in slowing disease progression and preventing irreversible vision loss.
Evangelia Gkaragkani, MD, FEBOophth | E: evangelia.gkaragkani@fa2.ch
Gkaragkani is a Glaucoma Consultant at Jules Gonin Eye Hospital in Lausanne, Switzerland, and in Laser Vision Ophthalmology Clinic in Athens, Greece.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.